Increased SOCS1 and SOCS3 expression in papillary thyroid carcinoma and its association with prognosis.

Eur Rev Med Pharmacol Sci

Department of Pathology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.

Published: July 2023

Objective: The majority of patients with papillary thyroid carcinoma (PTC) have good outcomes, although the identification of new predictors of a poor prognosis would be beneficial. Chronic thyroiditis is a precancerous condition in which proinflammatory cytokines enhance biologically aggressive features. This study investigated the expression of suppressor of cytokine signaling proteins (SOCS) 1 and 3, which are negative feedback inhibitors, in PTC and benign thyroid nodules (BTN), and analyzed the relations among biomarker expression, pathological prognosis, and clinical features.

Patients And Methods: The pathological materials and clinical data of 100 patients with PTC and 40 with BTN were retrospectively analyzed. Immunohistochemical SOCS1 and SOCS3 staining were performed. Besides comparing SOCS1 and SOCS3 expression between PTC and BTN, we analyzed the expression according to pathological factors and clinical variables.

Results: The expression levels of the proteins were significantly higher in PTC than in BTN (p=0.001). SOCS1 expression was higher in older patients with PTC than in younger patients (p=0.001). Unlike SOCS1, SOCS3 was related to the risk group; these groups were distinguished based on the American Thyroid Association (ATA) risk stratification system (p=0.001). SOCS3 was also significantly related to lymph node involvement (p=0.007), capsule invasion (p=0.005), and extrathyroid extension (p=0.009).

Conclusions: The increased SOCS1 and SOCS3 expression in PTC confirms their roles in thyroid carcinogenesis. Antibodies to both SOCS1 and SOCS3 might aid the diagnosis of PTC through immunohistological staining. SOCS3 provides information on lymph node status and aids risk stratification.

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202307_33134DOI Listing

Publication Analysis

Top Keywords

socs1 socs3
24
socs3 expression
12
ptc btn
12
increased socs1
8
socs3
8
expression
8
papillary thyroid
8
thyroid carcinoma
8
ptc
8
btn analyzed
8

Similar Publications

Diabetes mellitus type 2 (DMT2) promotes Achilles tendon (AS) degeneration and exercise could modulate features of DMT2. Hence, this study investigated whether tenocytes of non DMT2 and DMT2 rats respond differently to normo- (NG) and hyperglycemic (HG) conditions in the presence of tumor necrosis factor (TNF)α or cyclic stretch. AS tenocytes, isolated from DMT2 (fa/fa) or non DMT2 (lean, fa/+) adult Zucker Diabetic Fatty (ZDF) rats, were treated with 10 ng/mL TNFα either under NG or HG conditions (1 g/L vs.

View Article and Find Full Text PDF

Background: Polymorphonuclear neutrophils (PMN) activation by monosodium urate crystals (MSU) is crucial to acute gouty arthritis and subsequent spontaneous remission within 7-10 days. Activated PMNs release neutrophil extracellular traps (NETs) that entrap MSU crystals, forming NET-MSU aggregates. Whether NET-MSU aggregates contribute to the resolution of acute inflammation remains to be elucidated.

View Article and Find Full Text PDF

ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B.

Front Immunol

November 2024

Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for Clinical Immunology Laboratory Test, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Background: The varying individual responses to Pegylated interferon-α (Peg-IFNα) in patients with chronic hepatitis B (CHB) pose significant hurdles in treatment optimization, and the underlying mechanisms remain unclear.

Objective: We aimed to identify genetic polymorphisms influencing the efficacy of Peg-IFNα in patients with HBeAg-positive CHB, with the goal to predict Peg-IFNα response before treatment.

Methods: We employed an Asian Screening Array analysis involving 124 HBeAg-positive CHB patients treated with Peg-IFNα.

View Article and Find Full Text PDF

Relapsing-remitting multiple sclerosis is associated with changes in Jak/STAT pathways in immune cells, but the influence of disease-modifying drugs on these pathways is poorly understood. The aim of this study was to evaluate the impact of first-line disease-modifying drugs used in treatment of RRMS on expression of the STAT pathway and T-cell-related genes in the blood and on serum concentrations of sgp130 and TGF-β1 in women, as well as on the level of phosphorylated STAT3 and STAT5 proteins in T cells of untreated patients and heathy controls. Expression of STAT1, STAT3, STAT5A, STAT5B, SOCS1, SOCS3, FOXP3, IKZF2, RORC and ICOS genes in the blood of untreated RRMS patients, in the blood of patients treated with interferon-β, glatiramer acetate, dimethyl fumarate or teriflunomide and in the blood of healthy controls was evaluated using droplet digital PCR.

View Article and Find Full Text PDF

STAT1 as a potential therapeutic target to treat bladder cancer.

Int J Clin Exp Pathol

September 2024

Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology Kunming 650101, Yunnan, China.

Background: Previous studies have reported that STAT1 (Signal Transducer and Activator of Transcription 1) is associated with multiple tumor progression. This study aimed to investigate the role and related mechanisms of STAT1 in bladder cancer.

Methods: STAT1 expression in bladder cancer tissues and human bladder cancer cell lines was assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!